100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Contract Awards
Delivery Order HHSN272201100012I-HHSN27200006
Award Date
9/18/14
Potential Completion Date
9/29/15
Potential Value
$147K
Overview
Contacts
Activity
1
Transactions
1
Subawards
Opportunity Stack
Similar Awards
Federal Agency
NIAID DEA OA Acquisitions
Awardee
Southern Research Institute CDZJAJJHJMH5
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
PSC Category
AN11 - Health R&D Services; Health Care Services; Basic Research
Federal Contract Vehicle
In Vitro Antimicrobial Assessments 2011-2018
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Birmingham, AL 35205, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
3
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
In Vitro Antimicrobial Assessments 2011-2018
Master IDIQ
HHSN272201100012I
Indefinite Delivery Contract
HHSN272201100012I-HHSN27200006
Delivery Order
Description
OTHER FUNCTIONS - IN VITRO ASSESSMENT OF ANTIMICROBIAL ACTIVITY
Posted 9/18/14
5
1
Name
Description
Solicitation Number
FederalAgency
Type
PostedDate
IN VITRO ASSESSMENTS FOR ANTIMICROBIAL ACTIVITY
Added: Sep 02, 2009 11:39 am IntroductionThe National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID's Division of Microbiology and Infectious Diseases (DMID) has a requirement for developing and providing in vitro assays in order to advance the development of therapeutics for infectious diseases.Description NIAID's role in developing medical products to counter emerging, re-emerging and other infectious diseases, as well as agents of bioterrorism, is part of a larger national strategy, involving multiple governmental agencies. As such, NIAID supports integrated efforts in basic and applied research, product development, and technology development based on national priorities for medical products. Since 2001, NIAID has established a comprehensive infrastructure with extensive resources that support all levels of biodefense research. With this solid framework of research and product development resources for biodefense in place, NIAID is now transitioning this infrastructure to provide the flexibility required to meet the challenges of emerging, re-emerging and other infectious diseases in addition to biodefense.The use of in vitro assays helps advance our understanding of infectious diseases as well as the development of therapeutics and vaccines. Therefore, DMID is committed to developing and providing in vitro assays to benefit the research community and public health.For the most part, in vitro assay services and other research resources are currently provided tough multiple, specialized programs. DMID now seeks to adopt an integrated approach to the provision of services and resources by creating unified, comprehensive, coordinated programs. This strategy is being employed to: advance science by promoting cross-fertilization across and within disciplines and approaches; serve the research community more conveniently; achieve efficient use of resources tough economy of scale and avoidance of duplication; and provide the flexibility needed to respond to changing priorities. Accordingly, DMID is establishing the In Vitro Assessments for Antimicrobial Activity program, which will utilize the Indefinite Delivery, Indefinite Quantity (IDIQ) contract mechanism.Under IDIQ contracts, base contract awards are made to multiple offerors that successfully propose a general approach to the technical requirements of the solicitation, providing a guaranteed minimum award. Task Orders for specific tasks requiring specialized expertise are competitively solicited and funded within the program Contractor pool. DMID is replacing multiple pathogen or class specific solicitations with one broad IDIQ solicitation for multiple contracts to cover all areas of current and potential future interests.The work under this acquisition has been broken into five Parts. Work under Parts A, B and D require Biosafety Levels (BSL) 1 tough 3, and compliance with Select Agent Regulations tough the Centers for Disease Control (CDC) and/or the United States Department of Agriculture (USDA) (42 CFR Part 73, 7 CFR Part 331, and/or 9 CFR Part 121). For offerors submitting proposals for more than one Part, separate Technical and Business Proposals are required for each Part. Offerors may not submit more than one proposal per Part A, B, C, D or E.1. Part A - Bacteria and Fungi - Will support the development and use of in vitro assays for routine screening of products against a wide range of bacterial and fungal pathogens, to include all bacteria and fungi on the NIAID Category A, B and C Priority Pathogens list (http://www3.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/CatA.htm) and other bacterial and fungal pathogens that cause disease in humans.2. Part B - Viruses - Will support the development and use of in vitro assays for routine screening products against a wide range of viral pathogens, to include all viruses on the NIAID Category A, B and C Priority Pathogens list, and other viral pathogens that cause disease in humans.3. Part C - Parasites and Vectors - Will support the development and use of in vitro assays for routine screening of products against a wide range of parasitic pathogens, to include all parasites and vectors on the NIAID Category A, B and C Priority Pathogens list, and other parasitic pathogens that cause disease in humans. This Part also includes screening against cell lines from insect and other artopod vectors.4. Part D - Toxins - Will support the development and use of in vitro assays for routine screening of products against a wide range of toxins, to include all toxins on the NIAID Category A, B, and C Priority Pathogens list.5. Part E - Central Data Management System - Will support the development, implementation, operation, and maintenance of a Central Data Management System to support all activities conducted under Parts A, B, C and D. In order to qualify for work under Part E, Contractors must also qualify for one or more of Parts A-D. Offerors submitting a proposal under Parts A, B, C and/or D DO NOT have to submit a proposal for Part E.For the purposes of this acquisition:• Assays - in vitro procedures for determining the concentration, purity, and/or biological activity of a substance by measuring its effect on an organism, tissue, cell, enzyme or receptor preparation.• Products - broadly defined and include therapeutic substances targeting the host or the pathogen. • Pathogens - bacteria, viruses, parasites, toxins and fungi, including NIAID Category A, B and C Priority Pathogens.• Toxins - microbial toxins as they relate to human disease, and other toxins on the NIAID Category A, B and C Priority Pathogens list (http://www3.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/CatA.htm).• Vectors - insects or other artopods that carry pathogens from infected to uninfected hosts.• Pathogens of interest - must be pathogens which cause disease in humans; however surrogate human pathogens may be used for diseases where human pathogens cannot be studied. • Reagents - biochemical, genomic, molecular, cellular, and immunologic materials integral to research on these pathogens, toxins and vectors.The following factors will be considered when evaluating proposals:• adequacy and appropriateness of the general technical approach for in vitro assays, to include protocol and assay development, conduct of product susceptibility studies; soundness, feasibility and completeness of the technical approach to pathogen production and characterization.• adequacy, appropriateness and relevance of expertise, experience, qualifications, and availability of the key professional and technical staff with a project of similar size, scope, and complexity. • availability of adequate, accredited facilities, with biocontainment appropriate for the pathogens proposed; availability and appropriateness of equipment and other resources necessary for the proposed in vitro assays including IT systems, data management, and capabilities for the receipt, storage, shipping and inventory of products, pathogens, specimens, and reagents; and adequacy of institutional biosafety program.It is anticipated that multiple IDIQ base contracts will be awarded for a 7-year period of performance beginning on or about September 10, 2010.Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about September 18, 2009, and may be accessed tough FedBizOpps http://www.fedbizopps.gov/. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.
NIAID-DMID-NIHAI2009066
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
9/2/09, 11:39 AM
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
OTHER FUNCTIONS - IN VITRO ASSESSMENT OF ANTIMICROBIAL ACTIVITY
Not listed
$147.3k
9/18/14